外源p53基因联合热疗和放射治疗76例晚期软组织肉瘤临床研究

doi:10.3760/cma.j.issn.1004-4221.2017.05.014

Abstract
Figure/Table
References()
Related Citation (8)
Read Tracking
Download Tracking

Download: PDF (763 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract

Objective To evaluate the efficacy and safety of recombinant adenovirus-p53(rAdp53) injection combined with radiotherapy and hyperthermia in the treatment of unresectable advanced soft tissue sarcoma.Methods In this retrospective study, we evaluated 76 patients with unresectable advanced primary or recurrent soft tissue sarcoma treated in our hospital from November 2005 to November 2012. These patients received radiotherapy and hyperthermia with rAdp53(p53 group, n=41) or without rAdp53(control group, n=35). rAdp53((1-2)×10¹² viral particles each time, once a week, 8 times on average) was injected into the tumor or infused into the pelvic cavity. Radiotherapy (2 Gy each time, 5 times a week) was performed for the planning target volume at 56.3±5.3 Gy in the p53 group and 58.1±4.2 Gy in the control group, with no significant difference between the two groups (P>0.05). Superficial or deep thermotherapy was employed 8 times on average (twice a week). Clinical features, response rate, time to progression (TTP), overall survival (OS), and adverse events were compared between the two groups (P>0.05). The Kaplan-Meier method was used to calculate OS;the log-rank test was used for survival difference analysis and univariate prognostic analysis;the chi-square test was used for comparison of categorical data. Results At 2 months after treatment, the p53 group had significantly increased response rate (partial response+ complete response+ stable disease)(85% vs. 54%, P=0.003) and local control rate (49% vs. 23%, P=0.020) as well as prolonged TTP (12 months vs. 5 months, P=0.010) and OS (48 months vs. 31 months, P=0.049), as compared with the control group. No adverse events caused by radiotherapy and hyperthermia except transient fever were seen in the two groups. Conclusions Concurrent radiotherapy and hyperthermia combined with rAdp53 injection is effective and safe for patients with advanced soft tissue sarcoma.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Xiao Shaowen
	Xu Yizhi
	Zhang Shanwen
	Liu Changqing
	Fang Zhiwei
	Bai Chujie
	Li Dongming
	Li Yongheng
	Cai Yong
	Sun Yan
	Zheng Baomin
	Su Xing
	Xu Gang

Key words： Recombinant adenovirus p53 Radiotherapy Hyperthermia Soft tissue sarcoma

Received: 17 March 2017

Corresponding Authors: Zhang Shanwen,Email:zhangshw4641@sina.com

Cite this article:

Xiao Shaowen,Xu Yizhi,Zhang Shanwen et al. Clinical efficacy and safety of recombinant adenovirus-p53 combined with concurrent radiotherapy and hyperthermia in treatment of advanced soft tissue sarcoma:a study of 76 patients[J]. Chinese Journal of Radiation Oncology, 2017, 26(5): 546-549.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2017.05.014 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2017/V26/I5/546

[1] Neville HL,Raney RB,Andrassy RJ,et al. Multidisciplinary management of pediatric soft-tissue sarcoma[J].Oncology,2000,14(10):1471-1481,1482-1476,1489-1490.
[2] Scoggins CR,Pollock RE.Extremity soft tissue sarcoma:evidence-based multidisciplinary management[J].J Surg Oncol,2005,90(1):10-13.
[3] Sherman KL,Wayne JD,Bilimoria KY.Overcoming specialty bias:another important reason for multidisciplinary management of soft tissue sarcoma[J].JAMA Surg,2013,148(7):640.DOI:10.1001/jamasurg.2013.143.
[4] Linch M,Miah AB,Thway K,et al. Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies[J].Nat Rev Clin Oncol,2014,11(4):187-202.DOI:1038/nrclinonc.2014.26.
[5] Tseng WW,Amini B,Madewell JE.Follow-up of the soft tissue sarcoma patient[J].J Surg Oncol,2015,111(5):641-645.DOI:10.1002/jso.23814.
[6] Carson DA,Lois A.Cancer progression and p53[J].Lancet,1995,346(8981):1009-1011.
[7] 肖绍文,张珊文,吕有勇,等.外源性p53基因对人胃癌细胞的放射增敏作用[J].北京大学学报(医学版),2001,33(5):427-431.
Xiao SW,Zhang SW,Lyu YY,et al. Effect of exogenous p53 gene on radiosensitivity of human gastric cancer cells[J].J Peking Univ (Med Sci Ed),2001,33(5):427-431.
[8] Li J,Pan J,Zhu X,et al. Recombinant adenovirus-p53(Gendicine) sensitizes a pancreatic carcinoma cell line to radiation[J].Chin J Cancer Res,2013,25(6):715-721.DOI:10.3978/j.issn.1000-9604.2013.11.12.
[9] 张珊文,肖绍文,吕有勇.腺病毒介导p53基因对人胃癌细胞热增敏的作用[J].中华物理医学与康复杂志,2002,24(8):489-492.
Zhang SW,Xiao SW,Lyu YY.The effect of adenovirus mediated p53 gene on human gastric cancer cells[J].Chin J Phys Med Rehabilit,2002,24(8):489-492.
[10] Pan JJ,Zhang SW,Chen CB,et al. Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma[J].J Clin Oncol,2009,27(5):799-804.DOI:10.1200/JCO.2008.18.9670.
[11] Zhang S,Xu G,Liu C,et al. Clinical study of recombinant adenovirus-p53(Adp53) combined with hyperthermia in advanced cancer (a report of 15 cases)[J].Int J Hyperthermia,2005,21(7):631-636.
[12] Li JL,Cai Y,Zhang SW,et al. Combination of recombinant adenovirus-p53 with radiochemotherapy in unresectable pancreatic carcinoma[J].Chin J Cancer Res,2011,23(3):194-200.DOI:10.1007/s11670-011-0194-0.
[13] Hupp TR,Hayward RL,Vojtesek B.Strategies for p53 reactivation in human sarcoma[J].Cancer Cell,2012,22(3):283-285.DOI:10.1016/j.ccr.2012.08.020.
[14] Ganjavi H,Gee M,Narendran A,et al. Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines:sensitization to cisplatin and doxorubicin[J].Cancer Gene Ther,2005,12(4):397-406.
[15] Wilson JM.Gendicine:the first commercial gene therapy product[J].Hum Gene Ther,2005,16(9):1014-1015.
[16] Kaufmann KB,Buning H,Galy A,et al. Gene therapy on the move[J].EMBO Mol Med,2013,5(11):1642-1661.DOI:10.1002/emmm.201202287.